Sugi Predict

Sugi Predict / Compounds / SCHEMBL7520223

SCHEMBL7520223

SCHEMBL7520223

Cc1oc2c(C)c3oc(=O)cc(C)c3cc2c1CNCCCCN(CCCl)CCCl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 3/20 0.40
▸ MAOA P21397 2/20 0.40
▸ L3MBTL1 Q9Y468 5/20 0.38
▸ KDM4E B2RXH2 7/20 0.37
▸ ALDH1A1 P00352 6/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ HTR2C P28335 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ ADORA2A P29274 1/20 0.37
▸ MAPT P10636 2/20 0.35
▸ HSD17B10 Q99714 2/20 0.35
▸ UBE2N P61088 1/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ POLB P06746 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ ERAP1 Q9NZ08 2/20 0.35
▸ GLA P06280 2/20 0.35
▸ GAA P10253 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7528193 0.97 MAOB (0.40) MAOBMAOAL3MBTL1KDM4EALDH1A1
SCHEMBL7524945 0.87 MAOB (0.40) MAOBMAOAL3MBTL1KDM4EALDH1A1
SCHEMBL7522508 0.86 MAOB (0.40) MAOBMAOAL3MBTL1KDM4EALDH1A1
SCHEMBL7525134 0.86 MAOB (0.40) MAOBMAOAL3MBTL1KDM4EALDH1A1
SCHEMBL3359444 0.83 MAOA (0.41) MAOBMAOAL3MBTL1KDM4EALDH1A1
Hydrochloric Acid SCHEMBL4193524 0.82 MAOA (0.41) MAOBMAOAL3MBTL1KDM4EALDH1A1
SCHEMBL3360003 0.82 MAOA (0.41) MAOBMAOAL3MBTL1KDM4EALDH1A1
SCHEMBL8903963 0.82 MAOA (0.41) MAOBMAOAL3MBTL1KDM4EALDH1A1
SCHEMBL7521144 0.82 MAOA (0.40) MAOBMAOAL3MBTL1KDM4EALDH1A1
SCHEMBL3360474 0.82 MAOA (0.42) MAOBMAOAL3MBTL1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020182581-A1 Treating blood or blood products with compounds which have a mustard, aziridinium or aziridine group and a nucleic acid binding group CERUS CORPORATION (US) 2002-12-05 — — US disclosed
US-6410219-B1 DECTIONN OF PATHOGEN DEACTION OF PATHOGEN BY COMPLEXING CERUS CORPORATION 2002-06-25 — — US disclosed
US-6143490-A IN VITRO METHOD FOR DEACTIVATION OF VIRAL, BACTERIAL, OR PROTOZOAN PATHOGEN BY ADDING COMPOUND CONSISTING OF INTERCALATOR NUCLEIC ACID BINDING LIGAND AND AN ATTACHED MUSTARD GROUP, TREATING THE MIXTURE, AND RECOVERING BLOOD CERUS CORPORATION (US) 2000-11-07 — — US disclosed
EP-0773716-A4 TREATING RED BLOOD CELL SOLUTIONS WITH ANTI-VIRAL AGENTS CERUS CORP (US) 1999-08-04 — — EP disclosed
EP-0773716-A1 TREATING RED BLOOD CELL SOLUTIONS WITH ANTI-VIRAL AGENTS Cerus Corporation (US) 1997-05-21 — — EP disclosed
WO-1996039818-A1 TREATING RED BLOOD CELL SOLUTIONS WITH ANTI-VIRAL AGENTS CERUS CORPORATION (US) 1996-12-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020182581-A1 Treating blood or blood products with compounds which have a mustard, aziridinium or aziridine group and a nucleic acid binding group ADAR, CD99, AAAS MAOB 2679/4885MAOA 3813/4885L3MBTL1 1266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.